Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Bioshares Biotech Summit 2024
17 slides from Rhythm Biosciences's conference presentation, Jul 12, 2024
Slide 1: Bioshares 2024 Investor Presentation
Bioshares 2024 Investor Presentation 12 JULY 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology. Rhythm’s initial product, ColoSTAT® is intended to be a simple, affordable blood test for the early detection of colorectal cancer Developing alternati
Slide 4: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY 0.6 Share Price (at 9 July 2024) $0.06 0.5 0.4 Shares on Issue 248.5M 0.3 Unlisted Options 21M 0.2 Market Capitalisation $14.9M 0.1 Cash in Bank (31 Mar 2024) $1.7M 0 03 Jul 03 Aug 03 Sep 03 Oct 03 Nov 03 Dec 03 Jan 03 Fe
Slide 5: Introducing our Clinical Advisory Board
Introducing our Clinical Advisory Board Sally Prof Prof Benton Jon Emery Finlay Macrae Consultant Clinical Biochemist and Herman Professor of Primary Care Cancer Head of Colorectal Medicine and Genetics at Clinical Lead for Clinical and Specialist Research at the University of Melbourne, and The Roy
Slide 6: Cancer is an increasing burden on global healthcare systems
Cancer is an increasing burden on global healthcare systems The role of cancer diagnostics remains critical to public health Estimated % rise in all cancers Estimated number of worldwide 2022 to 2050 prevalent cases in 5 years from 2022 Males and Females, Age 0-85+ RHY focus Breast 8.2m Colorectum
Slide 7: Cancer diagnostic interventions
Cancer diagnostic interventions Multiple Diagnostic decisions support an individual through the patient journey MONITORING & MINIMAL RESIDUAL SCREENING DISEASE DETECTION Surveillance PHARMA- COGENOMICS Detection & DRUG TRIAGE SELECTION PHASES Drug Therapy OF DISEASE Diagnosis Surgical SURGICAL Thera
Slide 8: Cancer diagnostic interventions differ in their complexity and scale
Cancer diagnostic interventions differ in their complexity and scale TECHNICAL COMPLEXITY SCREENING CONFIRMATION / TRIAGE SURGICAL MARGINS MINIMAL RESIDUAL DISEASE PHARMACOGENOMICS PROGNOSIS SIZE OF STUDY/FOLLOW-UP TIME Note: Size of circles and relative position is not quantitative, and positions a
Slide 9: Colorectal cancer (CRC) is treatable and often curable, yet is the second leading cause of cancer death globally
Colorectal cancer (CRC) is treatable and often curable, yet is the second leading cause of cancer death globally CRC is a progressive disease in which epithelial cells GLOBAL BURDEN IN 2020 in the colon or rectum grow out of control² 1.93 million new cases Adenoma ~940,000 deaths¹ Stage 0 RANK: MOST
Slide 10: First major clinical performance evaluation
First major clinical performance evaluation Prospective, multi-centre study to evaluate the clinical performance of the ColoSTAT® for the detection of CRC¹ STUDY DESIGN PRIMARY ENDPOINT Blood-based assay The primary endpoint was to evaluate ColoSTAT® performance compared to N= 989 patients, aged 40
Slide 11: Customer feedback has shaped our strategy
Customer feedback has shaped our strategy CUSTOMER & STAKEHOLDER FEEDBACK FASTER TURNAROUND/ 1 High volume testing dependent upon automation MAINTAIN LOW COGS 2 QUALITY Reliable supply chain from raw materials to finished kit LOWER RISK ROUTE 3 Lower complexity clinical application for ColoSTAT® TO
Slide 12: Faster turnaround time, lower cost, updated & simplified ColoSTAT Kit
Faster turnaround time, lower cost, updated & simplified ColoSTAT® Kit FASTER TAT / MAINTAIN LOW COGS QUALITY Multiplex Planar – Five Plates to a Single Plate LOWER RISK Based ELISA (Five reagents to a single kit) ROUTE TO MARKET ROBUST PRODUCT PIPELINE Reduced Cost Materials, Packaging and Transpor
Slide 13: Creating a pragmatic, quality-first mindset
Creating a pragmatic, quality-first mindset FASTER TAT / MAINTAIN LOW COGS QUALITY Improved Quality Tools LOWER RISK Quality Management System: eQMS ROUTE TO MARKET ROBUST PRODUCT PIPELINE Improved Quality Mindset Go to Gemba End-End Quality Managing the entire supply chain 12 © Rhythm Biosciences 2
Slide 14: Initial focus on disease detection for symptomatic patients
Initial focus on disease detection for symptomatic patients TECHNICAL COMPLEXITY FASTER TAT / MAINTAIN LOW COGS QUALITY LOWER RISK ROUTE TO MARKET SCREENING ROBUST PRODUCT PIPELINE CONFIRMATION / TRIAGE SIZE OF STUDY/FOLLOW-UP TIME Note: Size of circles and relative position is not quantitative, and
Slide 15: Platform technology expansion pipeline
Platform technology expansion pipeline FASTER TAT / MAINTAIN LOW COGS STAGE 1 STAGE 2 STAGE 3 STAGE 4 STAGE 5 QUALITY INITIATION FORMULATION DESIGN & FINAL Product Launch Opportunity and Concept and DEVELOPMENT VALIDATION & Post-Launch Risk Analysis Feasibility Verification, Validation, Opportunity
Slide 16: Refining our Clinical Development and Market Access plan
Rhythm’s short-term priorities for Q1 Refining Assay Development Complete development of multiplex assay our Clinical Market Definition Development Clearly define and quantify triage market in selected geographies and Market Market Access Access plan Confirm evidence requirements and regulatory requ
Slide 17: Thank You!
ingeal RHYTHM BIOSCIENCES david.atkins@rhythmbio.com www.rhythmbio.com